中晚期胃肠道肿瘤患者采用香菇多糖联合化疗的疗效

Effect of lentinan combined with chemotherapy in patients with gastrointestinal tumors in middle and advanced stages

目的 探讨香菇多糖联合化疗治疗中晚期胃肠道肿瘤的疗效。方法 选取本院收治的中晚期胃肠道肿瘤患者60例分为观察组(n=30)和对照组(n=30),2组均给予FOLFOX4(奥沙利铂+叶酸钙+氟尿嘧啶)方案化疗,观察组在此基础上于化疗前3d开始给予香菇多糖治疗。2个化疗疗程后比较2组近期临床疗效、T细胞亚群及NK细胞活性变化、生活质量Karnofsky评分、体质量变化及不良反应。结果 观察组近期临床疗效显著优于对照组(P<0.05);治疗前,2组患者免疫功能指标、Karnofsky评分及体质量比较差异均无统计学意义(P>0.05);治疗后,观察组CD3^+、CD4^+、CD4^+/CD8^+及NK细胞较治疗前显著上升,CD8+较治疗前显著降低(P<0.05);对照组CD8+较治疗前显著升高,其他指标均下降(P<0.05);2组以上指标比较差异有统计学意义(P<0.05);治疗后,观察组Karnofsky评分、体质量下降程度及化疗不良反应发生率显著低于对照组(P<0.05)。结论 香菇多糖联合化疗治疗中晚期胃肠道肿瘤能显著提高患者免疫功能和临床疗效,改善生活质量及减轻体质量下降程度,并减轻化疗不良反应。

Objective To investigate the curative effect of lentinan combined with chemotherapy in the treatment of gastrointestinal tumors in middle and advanced stages. Methods A total of 60 patients with gastrointestinal tumors in middle and advanced stages who were admitted to the hospital were randomly divided into observation group ( n =30) and control group ( n =30). All patients were treated with FOLFOX4 (oxaliplatin, calcium folinate and fluorouracil) chemotherapy, while the observation group was additionally treated with lentinan at 3 days before chemotherapy. The short-term clinical curative effect, changes in T cell subsets, NK cell activity, Karnofsky scores of quality of life, weight and adverse reactions were compared. Results The clinical curative effect of the observation group was significantly better than that of the control group ( P <0.05). There was no significant difference in the immune function indexes, Karnofsky scores or weight between the two groups before treatment ( P >0.05). CD3^+, CD4^+, CD4^+/CD8^+ and NK cells in the observation group were significantly increased, while CD8 + was significantly decreased after treatment ( P < 0.05). CD8 + in the control group was significantly increased after treatment, while the other indicators were decreased ( P <0.05). There were statistically significant differences between groups in above indicators( P <0.05). The Karnofsky scores, the incidence of chemotherapy adverse reactions and weight of the observation group were significantly lower than that of the control group ( P < 0.05). Conclusion Lentinan combined with chemotherapy for gastrointestinal tumors in middle and advanced stages can significantly improve the immune function and quality of life, reduce weight decrease, and alleviate chemotherapy-relayed adverse reactions.